Plasminogen Activator Inhibitor-1 4G4G Genotype is Associated with Myocardial Infarction but Not with Stable Coronary Artery Disease

Overview

Journal J Thromb Thrombolysis

Specialty Cardiology & Vascular Diseases

Date 2007 Aug 28

PMID 17721742

Citations 15

Authors

Orhan Onalan

Gunay Balta

Ali Oto

Giray Kabakci

Lale Tokgozoglu

Kudret Aytemir

Cigdem Altay

Aytemiz Gurgey

Nasih Nazli

Affiliations

Soon will be listed here.

Abstract

Background: A case control study was conducted to test the hypothesis that plasminogen activator inhibitor type-1 (PAI-1) 4G/5G gene polymorphism confers an increased risk for myocardial infarction (MI) in patients with known coronary atherosclerosis.

Methods: One hundred fifty-six consecutive patients who presented with acute MI and 111 stable coronary artery disease (SCAD) patients with documented critical coronary artery stenoses were prospectively enrolled. PAI-1 4G/5G gene polymorphism and conventional atherosclerotic risk factors were studied in all patients. PAI-1 4G/5G gene polymorphism was studied in another 281 healthy blood bank donors.

Results: The frequency 4G4G genotype was significantly higher in the MI group as compared to SCAD group (32.7% vs. 15.3%, P = 0.001) while it was not statistically significant between MI and healthy control groups (32.7% vs. 26.0%, P = 0.136). Comparing with healthy controls SCAD group had significantly lower frequency of 4G4G genotype (P = 0.024). In comparison with SCAD group PAI-1 4G/4G genotype, male sex and smoking habits favored to MI in univariate analysis with a P value of less than 0.2. These variables were included in multivariate regression model to estimate the associated risk for MI. PAI-1 4G/4G genotype was the only independent variable (OR 2.67, 95%CI 1.43-4.96, P = 0.002) associated with MI in this regression model. Comparing with healthy control group 4G4G genotype was not associated with MI (OR 1.38, 95%CI 0.90-2.12). However, presence of 4G4G genotype had a protective effect against development of SCAD (OR 0.52, 96%CI 0.29-0.92).

Conclusion: Compared to patients with critical coronary stenoses, PAI-1 4G/4G genotype was found to be an independent predictor for development of MI in this population. PAI-1 4G4G genotype have a protective effect against development of high grade stable coronary stenoses.

Citing Articles

Integrative Genetic Approach Facilitates Precision Strategies for Acute Myocardial Infarction.

Khawaja M, Siddiqui R, Virani S, Amos C, Bandyopadhyay D, Virk H Genes (Basel). 2023; 14(7).

PMID: 37510245 PMC: 10379681. DOI: 10.3390/genes14071340.

Plasminogen Activator Inhibitor-1 Polymorphisms and Risk of Coronary Artery Disease: Evidence From Meta-Analysis and Trial Sequential Analysis.

Tabaei S, Omraninava M, Mehranfar S, Motallebnezhad M, Samaneh Tabaee S Biochem Genet. 2022; 60(5):1409-1445.

PMID: 35039979 DOI: 10.1007/s10528-021-10143-x.

Plasminogen Activator Inhibitor-1 4G/5G Polymorphism Contributes to Osteonecrosis of the Femoral Head Susceptibility: Evidence from a Systematic Review and Meta-analysis.

Sobhan M, Mahdinezhad-Yazdi M, Moghimi M, Aghili K, Jafari M, Zare-Shehneh M Arch Bone Jt Surg. 2019; 6(6):468-477.

PMID: 30637301 PMC: 6310193.

Genetic variants in the plasminogen activator inhibitor-1 gene are associated with an increased risk of radiation pneumonitis in lung cancer patients.

Liu B, Tang Y, Yi M, Liu Q, Xiong H, Hu G Cancer Med. 2017; 6(3):681-688.

PMID: 28211612 PMC: 5345627. DOI: 10.1002/cam4.1011.

Blood Biomarkers in Minor Stroke and Transient Ischemic Attack.

Li J, Wang Y Neurosci Bull. 2016; 32(5):463-8.

PMID: 27250628 PMC: 5563758. DOI: 10.1007/s12264-016-0038-5.

References

Iacoviello L, Burzotta F, Di Castelnuovo A, Zito F, Marchioli R, Donati M . The 4G/5G polymorphism of PAI-1 promoter gene and the risk of myocardial infarction: a meta-analysis. Thromb Haemost. 1998; 80(6):1029-30. View

Nordt T, Lohrmann J, Bode C . Regulation of PAI-1 expression by genetic polymorphisms. Impact on atherogenesis. Thromb Res. 2001; 103 Suppl 1:S1-5. DOI: 10.1016/s0049-3848(01)00292-4. View

Anderson J, Muhlestein J, Habashi J, Carlquist J, Bair T, Elmer S . Lack of association of a common polymorphism of the plasminogen activator inhibitor-1 gene with coronary artery disease and myocardial infarction. J Am Coll Cardiol. 1999; 34(6):1778-83. DOI: 10.1016/s0735-1097(99)00424-6. View

Hamsten A, de Faire U, Walldius G, Dahlen G, Szamosi A, Landou C . Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet. 1987; 2(8549):3-9. DOI: 10.1016/s0140-6736(87)93050-9. View

Canavy I, Henry M, Morange P, Tiret L, Poirier O, Ebagosti A . Genetic polymorphisms and coronary artery disease in the south of France. Thromb Haemost. 2000; 83(2):212-6. View

Agirbasli M . Pivotal role of plasminogen-activator inhibitor 1 in vascular disease. Int J Clin Pract. 2005; 59(1):102-6. DOI: 10.1111/j.1742-1241.2005.00379.x. View

Hooper W, Lally C, Austin H, Renshaw M, Dilley A, Wenger N . The role of the t-PA I/D and PAI-1 4G/5G polymorphisms in African-American adults with a diagnosis of myocardial infarction or venous thromboembolism. Thromb Res. 2000; 99(3):223-30. DOI: 10.1016/s0049-3848(00)00236-x. View

Ye S, Green F, Scarabin P, Nicaud V, Bara L, Dawson S . The 4G/5G genetic polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene is associated with differences in plasma PAI-1 activity but not with risk of myocardial infarction in the ECTIM study. Etude CasTemoins de.... Thromb Haemost. 1995; 74(3):837-41. View

Iwai N, Shimoike H, Nakamura Y, Tamaki S, Kinoshita M . The 4G/5G polymorphism of the plasminogen activator inhibitor gene is associated with the time course of progression to acute coronary syndromes. Atherosclerosis. 1998; 136(1):109-14. DOI: 10.1016/s0021-9150(97)00191-3. View

10.

Hamsten A, Wiman B, de Faire U, Blomback M . Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med. 1985; 313(25):1557-63. DOI: 10.1056/NEJM198512193132501. View

11.

Libby P, Theroux P . Pathophysiology of coronary artery disease. Circulation. 2005; 111(25):3481-8. DOI: 10.1161/CIRCULATIONAHA.105.537878. View

12.

Hindorff L, Schwartz S, Siscovick D, Psaty B, Longstreth Jr W, Reiner A . The association of PAI-1 promoter 4G/5G insertion/deletion polymorphism with myocardial infarction and stroke in young women. J Cardiovasc Risk. 2002; 9(2):131-7. DOI: 10.1177/174182670200900209. View

13.

Betriu A, Pare J, Sanz G, Casals F, Magrina J, Castaner A . Myocardial infarction with normal coronary arteries: a prospective clinical-angiographic study. Am J Cardiol. 1981; 48(1):28-32. DOI: 10.1016/0002-9149(81)90568-3. View

14.

Shindo J, Ishibashi T, Kijima M, Nakazato K, Nagata K, Yokoyama K . Increased plasminogen activator inhibitor-1 and apolipoprotein (a) in coronary atherectomy specimens in acute coronary syndromes. Coron Artery Dis. 2001; 12(7):573-9. DOI: 10.1097/00019501-200111000-00008. View

15.

Ardissino D, Mannucci P, Merlini P, Duca F, Fetiveau R, Tagliabue L . Prothrombotic genetic risk factors in young survivors of myocardial infarction. Blood. 1999; 94(1):46-51. View

16.

Mansfield M, Stickland M, Wilson I, Grant P . Plasminogen activator inhibitor-1 promoter 4G/5G genotype and plasma levels in relation to a history of myocardial infarction in patients characterized by coronary angiography. Arterioscler Thromb Vasc Biol. 1997; 17(1):33-7. DOI: 10.1161/01.atv.17.1.33. View

17.

Carmeliet P, Moons L, Lijnen R, Janssens S, Lupu F, Collen D . Inhibitory role of plasminogen activator inhibitor-1 in arterial wound healing and neointima formation: a gene targeting and gene transfer study in mice. Circulation. 1997; 96(9):3180-91. DOI: 10.1161/01.cir.96.9.3180. View

18.

Kohler H, Grant P . Plasminogen-activator inhibitor type 1 and coronary artery disease. N Engl J Med. 2000; 342(24):1792-801. DOI: 10.1056/NEJM200006153422406. View

19.

Redmond E, Cullen J, Cahill P, Sitzmann J, Stefansson S, Lawrence D . Endothelial cells inhibit flow-induced smooth muscle cell migration: role of plasminogen activator inhibitor-1. Circulation. 2001; 103(4):597-603. DOI: 10.1161/01.cir.103.4.597. View

20.

Dawson S, Hamsten A, Wiman B, Henney A, Humphries S . Genetic variation at the plasminogen activator inhibitor-1 locus is associated with altered levels of plasma plasminogen activator inhibitor-1 activity. Arterioscler Thromb. 1991; 11(1):183-90. DOI: 10.1161/01.atv.11.1.183. View